The treatment of breast cancer is associated with strong commercial opportunity because of the disease’s high incidence, long treatment durations, and multiple lines of therapy. The CDK4/6…
Immune checkpoint inhibitors have revolutionized the treatment landscape for bladder cancer and upper tract urothelial carcinoma (UTUC). Initially confined to advanced disease, the anti-PD-1…
The multi-billion-dollar non-small-cell lung cancer (NSCLC) market is highly dynamic, with a plethora of approved therapies but still a high unmet need. Immune checkpoint inhibitors such as…
The small-cell lung cancer (SCLC) treatment landscape is dominated by chemotherapy and chemoradiotherapy. In the last 30 years, only two immunotherapies have been approved in this indication:…
Doublet or triplet chemotherapy alone or in combination with angiogenesis inhibitors remains the cornerstone of treatment for metastatic colorectal cancer. Patients without RAS mutations also…
Hormonal agents dominate the treatment landscape for prostate cancer and are routinely used in all lines of therapy. Next-generation hormonal treatments have expanded beyond metastatic castrate-…
Approximately 40% of gastric and gastroesophageal junction (GEJ) adenocarcinoma patients present with metastasis, and half of patients with localized disease progress to metastatic disease…
Pancreatic adenocarcinoma is an aggressive malignancy associated with an extremely poor prognosis and high lethality. The metastatic setting is the largest drug-treatable population in pancreatic…
The ovarian cancer treatment landscape has been transformed by the angiogenesis inhibitor bevacizumab and the poly ADP ribose polymerase (PARP) inhibitors Lynparza (AstraZeneca / Merck & Co.),…
The gastroesophageal cancer therapy market (including gastric, gastroesophageal junction, and esophageal cancer) is rapidly evolving and experiencing substantial growth, largely driven by the…
Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus. It consists of deep vein thrombosis (DVT) and pulmonary embolism (PE), depending on the location of the obstruction…
Clarivate Epidemiology’s coverage of RAS comprises epidemiological estimates of key patient populations with the biomarker in the major mature pharmaceutical markets (the United States, France,…
CAR T-cell therapy is a novel approach to cancer adoptive immunotherapy. The ongoing regulatory reforms, such as the breakthrough therapy designation (BTD) and priority review pathway, have…
China’s biosimilar market has evolved rapidly over the past four years since the approval of Henlius Biotech’s HLX01—a biosimilar of Roche’s MabThera (rituximab)—in February 2019. As of 2022…